Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. pantreat

PANTREAT

Pancreatic cancer as a treatment target of Dwarfbody-Therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PANTREAT project word cloud

Explore the words cloud of the PANTREAT project. It provides you a very rough idea of what is the project "PANTREAT" about.

amc    investments    plan    significantly    amsterdam    cancer    off    aggressive    pantreat    sound    form    team    additional    compiled    safe    dwarfbodies    intestinal    frontrunner    ranked    db    business    reports    molecular    ineffective    deals    superiority    licencing    transform    outcome    tx    2016    centers    competing    gastro    trial    published    weight    primarily    administering    basis    initial    2020    journals    anticancer    broadening    co    therapeutics    reg    treatment    attractive    spin    cancers    obtaining    proof    molecules    therapeutic    dwarfbody    portfolio    onwards    types    antibodies    grants    market    supportive    company   

Project "PANTREAT" data sheet

The following table provides information about the project.

Coordinator		 DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV 

Organization address
address: KWEEKDUINWEG 12
city: OVERVEEN
postcode: 2051 EL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website http://warfbody-therapeutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV NL (OVERVEEN) coordinator 50˙000.00

Map

 Project objective

Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANTREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANTREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More